Core Viewpoint - Kolon Biotech-B (06990) reported a significant decline in revenue for the six months ending June 30, 2025, with a 31.3% year-on-year decrease, leading to a loss attributable to equity shareholders of RMB 145 million [1] Financial Performance - The company achieved revenue of RMB 950 million, down 31.3% year-on-year [1] - Research and development expenses amounted to RMB 612 million, a decrease of 6.3% year-on-year [1] - The loss attributable to equity shareholders was RMB 145 million, with a loss per share of RMB 0.64 [1] Product Development and Commercialization - The company has received marketing approvals for sac-TMT (Jiatailai), Tagolizumab (Ketailai), and Cetuximab N01 (Datailai) and has commenced commercialization [1] - The company anticipates launching Botuzumab (Shutailai) in the Chinese market in the second half of 2025, pending regulatory communication and approval [1] - Total commercial sales for the first half of 2025 reached RMB 309.8 million, with Jiatailai accounting for 97.6% of sales [1] Accounts Receivable Management - All accounts receivable from drug sales were collected within the payment period, indicating efficient and stable cash flow management [1]
科伦博泰生物-B绩后涨超3% 中期收入9.5亿元 预期下半年于国内推出舒泰莱